Claire D'Abreu-Hayling
Chief Scientific Officer, Sandoz - Pioneering access for patients responsibly and sustainably
Sandoz•Basel, Switzerland
View LinkedIn ProfileExperience38+ Years
LevelCXO
Executive Overview
Claire D'Abreu-Hayling is the Chief Scientific Officer at Sandoz with over 30 years of experience in drug development. She oversees the company’s global product development network, including infrastructure strategy, pipeline execution, and talent management for both small molecules and biosimilars. Claire studied Chemistry and Pharmaceutical Analysis at the University of the West Indies and the University of London. Her leadership also emphasizes diversity and inclusion, promoting fair practices based on capabilities and experience at Sandoz.
Career Timeline
- SandozCurrentOct 2021–Present· 4 yrs 11 mos
- Chief Scientific OfficerCurrentJul 2022–Present
- Head Of Product DevelopmentOct 2021–Jun 2022
- Dec 2006–Oct 2021· 14 yrs 10 mos
- Head of Global Sterile R&DAug 2011–Oct 2021
- EU Regional Head of R&DJul 2009–Aug 2011
- Head of New Product Development - RuncornDec 2006–Jul 2009
- Jul 2002–Dec 2006· 4 yrs 5 mos
- Head of Analytical Technology2003–Dec 2006
- MDI Analytical ManagerJul 2002–2003
- Aug 1988–Dec 2002· 14 yrs 4 mos
- Analyst to Analytical Team LeaderAug 1988–Dec 2002
Education
Master's degree
Theology
Regents Theological College
Master's degree
Pharmaceutical Analysis and Quality Control
University of London
Bachelor's degree
Chemistry
The University of the West IndiesExecutive Relationship Map
Reports To
Claire D'Abreu-Hayling
Vice Chair & President
Chief Financial Officer
Chief Technology Officer
Chief Operating Officer
Skills & Expertise
Biosimilar DevelopmentComplex Gx DevelopmentProduct DevelopmentLeadershipMulti-cultural team buildingManagementResearch SkillsWritingStrategyAnalytical SkillsLogical Framework AnalysisCross-functional Team LeadershipCritical ThinkingPharmaceutical IndustryIn Silico GxDiversity & InclusionAbstract reasoning